

## Parenteral Form (Inj Sol) of Dextropropoxyphene HCL (Romidon/Stargen Greece)



### Overview

Indications: Relief of mild to moderate pain

Uses: Hospital use, for oncology patients, general surgery, post-operative analgesia.

Romidon is an **opioid analgesic** that covers the pharmaceutical therapeutic area between the NSAIDs and classic narcotics. It is used in hospitals as an alternative to morphine or codeine, as a low cost, effective, well established analgesic.

Clinical experience in Greece has shown less dependency and side effects in comparison with classic narcotics. Its use is well established for more than 40 years in the majority of hospitals in Greece, being physicians' first choice in post operative analgesia and the confrontation of moderate pain. Note that more than 9 million amps has been used the last 40 yrs, corresponding approximately to 12,000 patients per year, demonstrated high tolerance, efficacy and zero side effects.

The Parenteral Form of Propoxyphene was excluded from the withdrawal decision of European Committee (2010), applied for all products containing dextropropoxyphene in the forms of tabs & caps.

For the parenteral form the Committee considered that the risk of fatal overdose and abuse is limited, given the administration under hospital setting, the classification of these medicinal products as narcotic prescription and the lack of evidence of fatal overdose particularly of accidental overdose.

In 2013 the National Organization of Medicines (Greece) decided to lift the suspension of Romidon license and ever since the product is gaining its dominant position in the everyday clinical practice.